Obagi's Solubilized Benzoyl Peroxide Reduces Moderately Severe Acne

Obagi Medical announced the results of four studies of the CLENZIderm M.D. Acne Therapeutic Systems' two proprietary 3-step acne treatments. The data show that patients of all skin types with mild-to-moderately severe acne saw significant improvement in inflammatory and non-inflammatory lesions and reported high levels of patient satisfaction, lower levels of dryness and greater comfort when using the innovative formulation of solubilized 5% benzoyl peroxide (BPO) in the CLENZIderm M.D. Systems.

Key findings of the studies:

Two Studies of the Solubilized 5% BPO Serum Gel for Normal-to-Oily Skin

-- The first study showed that when compared to twice-daily treatment with a leading BPO/clindamycin combination product, the twice-daily monotherapy with the solubilized 5% BPO serum gel (CLENZIderm M.D.) resulted in a greater and more rapid reduction in the number of non- inflammatory and inflammatory lesions (42% vs. 28% and 70% vs. 61%, respectively, at week 4).

-- The second study showed that the 3-step CLENZIderm M.D. System demonstrated a moderate or greater overall improvement compared with previously used treatments and high patient satisfaction. A majority (up to 77%) of patients who participated in this multicenter observation study considered the CLENZIderm M.D. acne system more effective than prescription and over-the-counter acne medications they had used previously.

Two Studies of the Solubilized 5% BPO Lotion for Normal-to-Dry Skin

-- In the first study, the investigator found that compared to a leading BPO/clindamycin combination product, the once-daily use of CLENZIderm M.D. System for normal-to-dry skin provided comparable improvements by reducing the non-inflammatory count by a mean of 38% and reducing the inflammatory lesion count by a mean of 63% (versus 48% and 66%, respectively, with BPO/clindamycin).